ÂÜÀòÂÒÂ×

Michael J. Sofia is currently the Chief Scientific Officer at Arbutus Biopharma. Prior to this, they served as the Group Director of New Leads Chemistry at Bristol-Myers Squibb from June 1999 to August 2005. In this role, they were responsible for global capabilities in lead generation, early lead optimization, natural products and sample managment. Dr. Sofia then served as President, Chief Scientific Officer and Co-founder of OnCore Biopharma from July 2012 to March 2015. Michael was a member of the senior management team and operating committee with responsibility for the research and development function and general operational and licensing functions. Prior to OnCore Biopharma, Dr. Sofia was the Sr. Vice President of Chemistry, Site Head and Sr. Advisor at Gilead Sciences, Inc from January 2012 to January 2013. From July 1993 to May 1999, they served as Vice President of Discovery Research at Transcell Technologies / Intercardia Inc. Dr. Sofia began their career as a Senior Research Scientist at Eli Lilly from January 1989 to June 1993. Michael holds a Phd from Drexel University School of Medicine.

Michael J. Sofia Phd earned their Bachelor of Arts in Chemistry from Cornell University. Michael then went on to earn a Certificate in Pharmaceutical Management from The Wharton School. After that, they completed a Post-Doc in Organic Synthesis at Columbia University. Finally, they earned their Ph.D. in Organic Chemistry from the University of Illinois Urbana-Champaign.

Michael J. Sofia Phd reports to William H. Collier, President & CEO. They are on a team with David C. Hastings - CFO, Elizabeth Howard - EVP, General Counsel & Chief Compliance Officer, and Gaston Picchio - Chief Development Officer.